First Fecal Tagging Agent Approved for Virtual Colonoscopy

The test helps distinguish between true polyps vs. stool, reducing the number of false positives
The test helps distinguish between true polyps vs. stool, reducing the number of false positives

Bracco Diagnostics announced that the Food and Drug Administration (FDA) has approved Tagitol V (barium sulfate) oral suspension for use in adult patients undergoing a computer tomography colonography (CTC). Tagitol V is the first FDA-approved contrast imaging agent for this indication. 

A CTC is a non-invasive validated screening test for colorectal cancer (CRC) that offers a computer-simulated endoluminal view of the colon. Tagitol V, a low-volume fecal tagging agent, opacifies remaining stool in the colon for CT imaging. It visibly identifies residual feces by blending into the stool. Tagging retained material with radiopaque contrast can help distinguish between true polyps vs. stool, reducing the number of false positives. 

Related Articles

Barium sulfate is biologically inert and is opaque to x-rays due to its high atomic number. Barium sulfate acts as a positive contrast agent for radiographic studies.

Tagitol V will be available as a 40% w/v oral suspension in boxes containing three 20mL bottles; each bottle contains 8g barium sulfate.

For more information call (800) 257-5181 or visit BraccoImaging.com.